

1 Development and validation of a highly sensitive and specific electrochemical assay to quantify  
2 anti-SARS-CoV-2 IgG antibodies to facilitate pandemic surveillance and monitoring of vaccine  
3 response.

4

5 Samantha H. Chiang<sup>a</sup>, Michael Tu<sup>c</sup>, Jordan Cheng<sup>a</sup>, Fang Wei<sup>a</sup>, Feng Li<sup>a</sup>, David Chia<sup>b</sup>, Omai  
6 Garner<sup>b</sup>, Sukantha Chandrasekaran<sup>b</sup>, Richard Bender<sup>c</sup>, Charles M. Strom<sup>c,\*</sup>, David T.W. Wong<sup>a</sup>

7

8 Affiliations: <sup>a</sup> School of Dentistry, University of California, Los Angeles, CA, USA

9 <sup>b</sup> Department of Pathology and Laboratory Medicine, University of California David Geffen  
10 School of Medicine, Los Angeles, CA, USA

11 <sup>c</sup>Liquid Diagnostics, LLC, San Clemente, CA, USA (M. Tu, R. Bender, C. M. Strom)

12

13 Running Head: Electrochemical assay for anti-SARS-CoV-2 IgG

14

15 \*Address for correspondence: Charles M. Strom, Liquid Diagnostics, LLC, 2939 Calle Gaucho,  
16 San Clemente, CA 92673; strom@liquid-dx.com

17

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

## Abstract

Amperial™ is a novel assay platform that uses immobilized antigen in a conductive polymer gel followed by an electrochemical detection. A highly specific and sensitive assay was developed to quantify levels of IgG antibodies to SARS-CoV-2 in saliva. After establishing linearity and limit of detection we established a reference range of 5 standard deviations above the mean. There were no false positives in 667 consecutive saliva samples obtained prior to 2019. Saliva was obtained from 34 patients who had recovered from documented COVID-19 or had documented positive serologies. All of the patients with symptoms severe enough to seek medical attention had positive antibody tests and 88% overall had positive results.

We obtained blinded paired saliva and plasma samples from 14 individuals. The plasma was analyzed using an EUA-FDA cleared ELISA kit and the saliva was analyzed by our Amperial™ assay. All 5 samples with negative plasma titers were negative in saliva testing. Eight of the 9 positive plasma samples were positive in saliva and 1 had borderline results. A CLIA validation was performed as a laboratory developed test in a high complexity laboratory.

A quantitative non-invasive saliva based SARSCoV-2 antibody test was developed and validated with sufficient specificity to be useful for population-based monitoring and monitoring of individuals following vaccination.

41           **Introduction**

42           A novel corona virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),  
43 has caused a global pandemic causing major disruptions world-wide (1). Multiple high-  
44 throughput PCR based tests have been developed that are reasonably sensitive and specific,  
45 however the same cannot be said for antibody testing, prompting The Center for Disease Control  
46 (CDC) to issue guidelines entitled “Interim Guidelines for COVID-19 Antibody Testing” (2).  
47 This publication describes the variability of in-home antibody tests and the lack of specificity  
48 required to make home-based antibody testing a valuable tool for epidemiologic surveillance.

49           Having a reliable self-collection antibody test may be of enormous help in epidemiologic  
50 studies of background immunity, testing symptomatic individuals without RNA based testing  
51 during their acute illness, and screening health care providers and first responders to establish  
52 prior COVID-19 infection. Such a test may also be valuable in following vaccinated patients to  
53 assess the kinetics of anti-SARS-CoV-2 antibody production following inoculation. Multiple  
54 serological tests based on serum or plasma have been developed and marketed, with ELISA and  
55 lateral flow methods predominating. However, many methods suffer from low sensitivities and  
56 specificities (2-6).

57           Antibodies begin appearing in the first week following the development symptoms. IgG,  
58 IgM, and IgA are detectable with IgA appearing somewhat earlier than IgG and IgM. Most  
59 patients seroconvert by 2 weeks following symptoms. Unlike IgA and IgM, IgG persists for  
60 several months following infection (7-9).

61           In a published study of 1,797 Icelandic individuals recovered from qPCR documented  
62 COVID-19 disease, 91% were IgG seropositive and antibody levels remained stable for 4 months  
63 after initial symptoms (10). Notably 2.3% of individuals quarantined due to exposure but

64 untested for virus, with negative qPCR results, tested positive for IgG antibodies. Of 18,609  
65 patients who were both unexposed and asymptomatic, the seropositivity rate was 0.3% (11).

66 Since health care systems are burdened with care for COVID-19 patients, having a test  
67 that does not require phlebotomy would be extremely beneficial. To that end, investigations have  
68 been carried out using home finger prick blood sampling and even some home blood spot testing  
69 lateral flow strips (5-7). However, home finger stick is invasive and not acceptable to some  
70 individuals, and requires a health care professional to administer the test to vulnerable  
71 individuals such as the elderly and children. In addition, home blood collection tests are less  
72 accurate than phlebotomy, with specificities less than 98%. In a low prevalence disease, the  
73 positive predictive value for a test with 98% specificity is less than 50% (7, 11).

74 Saliva is an oral fluid that is obtained easily and non-invasively. Proteomic studies show  
75 that the immunoglobulin profile in saliva is nearly identical to that of plasma (12). Therefore,  
76 saliva is an excellent medium for COVID-19 antibody measurement. There are several  
77 commercially available collection devices to facilitate saliva collection, stabilization of IgG, and  
78 transport.

79 A recently published study demonstrated excellent correlation between levels of COVID-  
80 19 antibodies in serum and saliva (13). In order to be useful in population-based screening and  
81 to determine individual immunity in exposed populations, a SARS-CoV-2 antibody test must be  
82 highly specific because of the low seroprevalence rate in the population (2, 14). In addition, the  
83 ability to quantify antibody levels is important for vaccine development and in monitoring for  
84 waning immunity (2,14). The only published saliva based assay for SARS-CoV-2 antibodies  
85 had only 89% sensitivity with 98% specificity (13), leading to a positive predictive value of only  
86 49% in a population with a 2% prevalence of COVID-19 exposure.

87           Our goal was to develop a non-invasive saliva based quantitative test for COVID-19  
88 antibodies with exquisite sensitivity. We reviewed existing literature to find the SARS-CoV-2  
89 antigen domain with the highest specificity and the ability to distinguish between the COVID-19  
90 virus and other related Coronaviruses. The S1 domain is the most specific in terms of cross  
91 reactivity with other Corona and other respiratory viruses. As recombinant S1 antigen is readily  
92 available from at least 2 vendors, we chose the S1 antigen for our assay development.

93           Levels of IgM and IgA deteriorate rapidly following recovery from COVID-19 infection;  
94 IgG levels remain detectable for several weeks to months (10). Since the intended use of our  
95 assay is for population-based screening and vaccine efficacy monitoring, we chose to assay IgG  
96 only.

97           The Amperial™ technology, formerly known as Electric Field Induced Release and  
98 Measurement (EFIRM™), is a novel platform capable of performing quantitation of target  
99 molecules in both blood and saliva (13-16). We developed quantitative Amperial™ assays for  
100 IgG, IgM, and IgA antibodies to the S1 spike protein antigen of SARS-CoV-2. This test is highly  
101 sensitive (>88%) and specific (>99.85%) for patients with COVID-19 infections and correlates  
102 well with plasma ELISA analysis. The unique assay described in this article is completely non-  
103 invasive, allows home-collection, is quantitative, and has shown no false positives in 667  
104 unexposed individuals, leading to a specificity of at least 99.6%. The widespread use of this test  
105 may be of great value in identifying individuals with prior exposure to SARS-CoV-2, to follow  
106 patients longitudinally to determine the kinetics of diminishing antibody concentration, and may  
107 be of special value in the longitudinal monitoring of vaccinated individuals to assess continued  
108 serologic immunity.

109

## 110 **Materials and Methods**

111           The schematic of the Amperial™ SARS-CoV-2 IgG antibody is shown in Figure 1. The  
112 principle of the Amperial™ platform is that a biomolecule (in this case SARS-CoV-2 Spike  
113 protein S1 antigen) is added to a liquid pyrrole solution that is then pipetted into the bottom of  
114 microtiter wells containing a gold electrode at the bottom of each well. After the solution is  
115 added to each well, the plate is placed into the Amperial™ Reader and subjected to an electric  
116 current leading to polymerization. This procedure results in each well becoming coated with a  
117 conducting polymer gel containing the S1 antigen. Following the polymerization, diluted saliva,  
118 plasma, or serum is added to the well. Specific anti-S1 antibodies bind to the S1 antigen in the  
119 polymer. After rigorous washing procedures, the bound antibody is detected by using  
120 biotinylated anti-human IgG and then the signal is amplified by a standard streptavidin /  
121 horseradish peroxidase reaction that produces an electric current measured by the Amperial™  
122 Reader in the nanoampere (nA) scale. The instrument is capable of accurately measuring current  
123 in the picoampere (pA) range, so the measurement is well within the ability of the instrument  
124 (13-16). The measurement of current rather than optical absorbance, as is done in the typical  
125 ELISA, has two important advantages over standard ELISA. Firstly, it allows precise  
126 quantitation of the amount of bound antibody and secondly, the measurement of current rather  
127 than optical absorbance allows increased sensitivity. Since antibody levels in saliva are lower  
128 than in plasma (13,15), this increased sensitivity is crucial. The precise details of the assay are  
129 described in the next paragraph.

130           COVID-19 Spike-1 Antigen (Sanyou-Bio, Shanghai, China) was diluted to a  
131 concentration of 6.25 µg / mL, added to each well of the microtiter plate, and co-polymerized  
132 with pyrrole (Sigma-Aldrich, St. Louis, MO) onto the bare gold electrodes by applying a cyclic

133 square wave electric field at 350 mV for 1 second and 1100 mV for 1 second. In total,  
134 polymerization proceeded for 4 cycles of 2 seconds each. Following this electro-polymerization  
135 procedure, 6 wash cycles were performed using 1x PBS with 0.05% Tween-20 (PBS-T) using a  
136 96-channel Biotek 405LS plate washer programmed to aspirate and dispense 400  $\mu$ L of solution  
137 per cycle.

138 Following the application of the polymer layer, 30  $\mu$ L of saliva diluted at a 1:10 ratio in  
139 Casein/PBS (Thermo-Fisher, Waltham, MA) was pipetted into each well and incubated for 10  
140 minutes at room temperature. Unbound components were removed by performing 6 wash cycles  
141 of PBS-T using the plate washer.

142 Biotinylated anti-human IgG secondary antibody (Thermofisher, Waltham, MA) at a  
143 stock concentration of 1.5 mg / mL was diluted 1:500 in Casein/PBS and 30  $\mu$ L pipetted to the  
144 surface of each well and incubated for 10 minutes at room temperature followed by 6 wash  
145 cycles using PBS-T. Subsequently, 30  $\mu$ L of Poly-HRP80 (Fitzgerald Industries, Acton, MA) at  
146 a stock concentration of 2  $\mu$ g / mL was diluted 1:25 in Casein/PBS, added to the wells, and  
147 incubated at 10 minutes at room temperature. Following a final wash using 6 cycles of PBS-T,  
148 current generation is accomplished by pipetting 60  $\mu$ L of 1-Step Ultra TMB (Thermofisher,  
149 Waltham, MA) to the surface of the electrode and placing the plate into the Amperial™ reader  
150 where current is measured at -200 mV for 60 seconds. The current in nA is measured 3 times for  
151 each well. The process for reading the entire 96 well plate requires approximately 3 minutes.

### 152 **Plasma Quantitative Amperial™ Assay for SARS-CoV-2 IgG**

153 The protocol is similar to the Amperial™ SARS-CoV-2 IgG antibody for saliva samples.  
154 Following the application of the polymer layer, 30  $\mu$ L of plasma diluted at a 1:100 ratio in  
155 Casein/PBS (Thermo-Fisher, Waltham, MA) was pipetted into each well and incubated for 10

156 minutes at room temperature. The standard curve for plasma contains the following points: 300  
157 ng / ml, 150 ng / ml, 75 ng / ml, 37.5 ng / ml, 18.75 ng / ml, and 0 ng / ml.

### 158 **Plasma SARS-CoV-2 ELISA Assay**

159 We purchased FDA EUA ELISA kits EUROIMMUN Anti-SARS-CoV-2 ELISA Assay  
160 for detection of IgG antibodies (EUROIMMUN US, Mountain Lakes, NJ). We processed  
161 samples exactly as described in the package insert.

### 162 **Human Subjects**

163 Volunteers, with prior positive qPCR tests for COVID-19 infection or positive antibody  
164 tests using currently available FDA EUA-cleared antibody tests were consented and responded to  
165 a questionnaire regarding severity of symptoms, onset of symptoms, and method of diagnosis  
166 (UCLA IRB #06-05-042). Severity of symptoms were self-graded on the following 7-point scale:

167 0: Asymptomatic

168 1: Mild (Barely noticed, perhaps slight fever and cough)

169 2: Moderate (felt moderately ill but did not need to seek medical care)

170 3: Sought medical Care but was not admitted to hospital

171 4: Hospitalized

172 5: Admitted to ICU

173 6: Placed on Ventilator

174 A set of 13 paired saliva and plasma samples were provided by the Orasure™ Company.

### 175 **Saliva Collection**

176 All COVID-19 samples were obtained using the Orasure™ FDA-cleared saliva collection  
177 device and used according to manufacturer instructions. The Orasure™ collection device  
178 consists of an absorbent pad on the end of a scored plastic wand. The individual places the pad

179 between cheek and gum for a period of 2 – 5 minutes. Subsequently the wand and pad are placed  
180 into a tube containing transport medium, the top of the stick is broken off, and the tube is sealed  
181 for transport. The sealed tube is placed into a zip-lock bag and shipped by any standard method.  
182 According to the package insert, samples are stable at ambient temperature for 21 days (see  
183 results below and Orasure™ website). An alternate sample collection method involves the  
184 individual swabbing the pad 4 times in the gingival tooth junction prior to placing the pad  
185 between the cheek and gum. This method has been shown to improve IgG yield in some patients  
186 with low antibody levels (personal communication).

187 Samples collected pre-2012 were used as controls. Saliva was collected from healthy  
188 individual volunteers at meetings of the American Dental Association between 2006 and 2011.  
189 Consent was obtained under IRB approval UCLA IRB #06-05-042. Both male and females,  
190 mostly non-smokers, 18-80 years of age, and a differing ethnicities were included. All subjects  
191 were consented prior to collection. Each subject expectorated ~ 5 mL of whole saliva in a 50cc  
192 conical tube set on ice. The saliva was processed within 1/2 hour of collection. Samples were  
193 spun in a refrigerated centrifuge @ 2600 X g for 15 minutes at 4°C. The supernatant (cell-free  
194 saliva) was then pipetted into two-2 mL cryotubes and 1.1 µL Superase-In (Ambion, Austin, TX)  
195 was added as a preservative. Each tube was inverted to mix. The samples were frozen in dry ice  
196 and later stored in -80°C.

## 197 **Results**

### 198 **Linearity**

199 Figure 2 demonstrates the dynamic range and linearity of the assay. In these experiments  
200 varying amounts of monoclonal human anti-S1 IgG was added to a saliva sample from a healthy  
201 volunteer and subjected to the assay. Figure 2A shows a range of 0.2 to 6 ng/ml. The Y-axis

202 shows amperage measured in nA. The X-axis represents spike-in concentrations of IgG. The  
203 assay begins to become saturated at about 3 ng / ml. Panel 2B shows dilutions down to 0.03 ng /  
204 ml to 0.6 ng / ml and shows linearity in that range. This allows us to create a standard curve  
205 containing the following points: 3 ng / ml, 1.5 ng / ml, 0.75 ng / ml, 0.375 ng / ml, 0.1875 ng /  
206 ml, and 0 ng / ml.

### 207 **Inhibition Assay**

208 In order to demonstrate the specificity for the assay on actual clinical samples, we used  
209 the saliva from 3 recovered patients who had high levels of SARS-CoV-2 antibodies and added  
210 exogenous S1 antigen in varying amounts prior to analysis on the Amperial™ assay. The  
211 exogenous S1 antigen should compete for binding sites and therefore extinguish the nA signal.  
212 Figure 3 shows the results of this experiment. The red, purple, and green represent 3 different  
213 patients. The X-axis demonstrates increasing concentration of exogenous S1 added to the saliva  
214 before subjecting it to the assay. As shown, saliva pre-incubated with S1 antigen extinguishes the  
215 detectable IgG signal proportionately, therefore demonstrating the specificity of the assay to S1  
216 antigen in clinical samples.

### 217 **Matrix Effects**

218 Since we are comparing samples collected by various methods, it is vital to determine  
219 if any significant matrix effects could interfere with data interpretation. We examined the 3  
220 different collection methods used in this study: Expectoration/centrifugation, Orasure™ without  
221 swabbing and Orasure™ with swabbing.

222 Two methods of collection using the Orasure™ Oral Fluid Collection Device were tested.  
223 The first method (non-swabbing) collects saliva by placing an absorbent pad into the lower gum  
224 area for 2-5 minutes and then placing the saturated collection pad into a preservative collection

225 tube. The second method (swabbing) adds the step of first gently rubbing the collection pad  
226 along gum line, between the gum and cheek, 5 times, before placing the device in the lower gum  
227 area for 2-5 minutes, and then immersing the saturated collection pad into the collection tube.  
228 Healthy donors (n=5) collected their saliva using these two different methods. The control pre-  
229 2012 samples were collected with an expectoration protocol for whole saliva collection (falcon  
230 tubes), processing (centrifuge), stabilization, and storage. Five samples collected by each of the 3  
231 methods and were analyzed in duplicate. The results are shown in Figure 4 under the heading  
232 “No spike in.” There are no differences among 3 sample types. We then added monoclonal  
233 human anti-S1 IgG to each sample and again ran them in duplicate (Figure 4) above caption  
234 Spike-in 1.5 ng / ml IgG. A non-parametric Student t-test was performed with no significant  
235 differences between any of the collection methods.

### 236 **Stability**

237 The Orasure™ collector is an FDA-cleared device for the analysis of anti-HIV IgG. The  
238 package insert describes a 21-day stability at ambient temperature. We wished to establish the  
239 stability of anti COVID-19 IgG using this collector. Passive whole saliva was collected from  
240 four healthy individuals using 50 mL falcon tubes and spiked with anti-Spike S1 IgG to reach a  
241 final concentration of 300 ng / ml. Aliquots of 1.75 mL of saliva were placed into 50 mL tubes  
242 and then the sponge of the Orasure™ collector was submerged into the saliva for five minutes  
243 and processed as described in Methods. The collected saliva was then aliquoted into PCR tubes  
244 and left at ambient temperature (21°C) for 0, 1, 3, 7, and 14 days before storage at -80°C. After  
245 14 days, samples were thawed and assayed using the anti-Spike S1 IgG Amperial™ assay to  
246 assess stability. At 14 days, 95% of the original signal remained, demonstrating the 14-day  
247 stability of anti-SARS-CoV-2 antibodies collected in Orasure™ containers (data not shown).

## 248 **Specificity and Reference Range**

249           Once we established no significant differences between the tube collection method and  
250 the Orasure™ collector method, we analyzed a series of 667 samples collected between 2006 and  
251 2009 at the annual meeting of the American Dental Association. Scatter plots of these data for  
252 both nA and ng / ml are shown in Figure 5A and 5B. We established the mean and standard  
253 deviation for both raw nA values and concentration in ng / ml. In order to maximize specificity,  
254 we selected a reference range  $> 5$  SD above the mean. A 5 sigma level would lead to a specificity  
255 of 99.9994%. In fact, we have never seen a healthy sample above the 5 sigma level. As will be  
256 seen, the sensitivity of the assay remains greater than 88% even with this rigorous specificity.

## 257 **Recovered COVID-19 Patients**

258           Figure 6 displays the scatter plot for 667 healthy controls and 34 volunteer patients who  
259 recovered from COVID-19 infection. All patients were a minimum of 14 days post onset of  
260 symptoms and some patients were as many as 15 weeks post symptoms. The 5 sigma cutoff is  
261 shown by the green dotted line. A more detailed discussion of the recovered patients appears in  
262 the following section. The data show that all healthy patients are negative and 30 of the 34  
263 recovered patients are positive. These data demonstrate a sensitivity of 88% and a specificity of  
264  $> 99.985\%$ . It is important to note that not all recovered patients have detectable antibody (10) so  
265 the 4 patients with undetectable antibody may be biologically negative and not the result of lack  
266 of sensitivity of the assay.

267           Figure 7 demonstrates the relationship of anti-S1 IgG levels to severity of symptoms.  
268 Table 1 is a tabular summary of these data. All patients who had severity indexes  $\geq 3$  (sought  
269 medical attention, admitted to hospital, admitted to ICU, on ventilator) had positive antibody  
270 levels. Although 4 patients with mild symptoms had antibody levels in the normal range, both

271 asymptomatic patients had appreciable antibody levels. These patients were close contacts of  
272 more severely affected patients. The highest antibody level recorded is severity index level 2  
273 patient (moderate symptoms, did not seek medical care). It is important to note that both  
274 asymptomatic patients had easily detectable antibody levels in saliva, suggesting this test may be  
275 useful in general population screening.

## 276 **Paired Saliva and Plasma Samples**

277 We obtained 14 paired, blinded plasma and saliva samples. The plasma was analyzed by  
278 an FDA EUA-cleared ELISA test purchased from EUROIMMUN (see Methods). The saliva  
279 samples, collected in Orasure™ buffer, were analyzed by the Amperial™ assay described in  
280 Methods. After unblinding, we discovered 8 recovered COVID patients and 5 healthy patients in  
281 this series. All 5 healthy patients were negative in both the saliva and plasma assays. In 7 of the 8  
282 recovered patients, both plasma and saliva tests were positive. There was one sample with a  
283 discrepancy between saliva and plasma, with the plasma positive and the saliva in the  
284 indeterminate range.

285 The EUROIMMUNE ELISA assay is a semi-quantitative assay and yields an absorbance  
286 ratio rather than a quantity. Figure 8 demonstrates the relationship between the saliva  
287 quantitative results and plasma absorbance ratio for the paired plasma and saliva samples. There  
288 is a clear relationship between the 2 levels, with the higher plasma absorbance ratios associated  
289 with higher saliva quantitation.

290 We developed a research quality assay to quantify anti-SARS-CoV-2 IgG levels in  
291 plasma (see Methods). We analyzed the 13 plasma samples using this assay. The results of this  
292 experiment are shown in Figure 9. Panel A shows a log / log plot of plasma versus saliva levels  
293 showing a clustering with high plasma levels associated with high saliva levels. Panel B shows

294 the box plot of these values, demonstrating that plasma levels are approximately 50X those of  
295 saliva. This observation explains the necessity for an extremely sensitive assay such as the  
296 Amperial™ assay in order to detect antibodies in saliva. Of note, the publication regarding saliva  
297 SARS-CoV-2 IgG detection reports levels of 25 – 60 mcg / ml, 1000 times less sensitive than our  
298 assay.

### 299 **Longitudinal Tracking of Antibody Levels**

300 Three of our volunteers supplied samples at weekly intervals so we could determine the  
301 stability of their antibody levels. Results appear in Figure 10. The 5 standard deviation cutoff is  
302 again shown with the dashed green line. All 3 patients continued to have detectable levels for  
303 more than 12 weeks, with the longest interval of 15 weeks. All tests were positive in all patients  
304 and antibody levels in all 3 patients remained clearly positive during the time interval studied.  
305 Patients C1 and C3 seem to have a rise in antibody level between 11 and 12 weeks post initial  
306 symptoms followed by a return to baseline level. Patient C2 might also have had a spike in  
307 antibody levels at 10 weeks. This may be result of the amnestic B-cell population becoming  
308 established. There is insufficient data at this time to determine if this is a generalized pattern.

### 309 **CLIA Evaluation**

310 We performed a full CLIA laboratory developed test evaluation for the Amperial™  
311 COVID-19 IgG Antibody test. The validation assayed 72 unaffected patients and 30 recovered  
312 patients and demonstrated 100% sensitivity and specificity. The intra-assay and inter-assay  
313 variability were 9.28% and 16.2% respectively.

### 314 **Discussion**

315 We have developed an exquisitely specific, sensitive, non-invasive saliva based  
316 quantitative assay for anti-SARS-CoV-2 IgG antibodies. Our goal was to create a quantitative

317 assay with sufficient positive predictive value to be useful to inform individuals regarding  
318 previous infection with COVID-19. By establishing a reference range of 5 sigma above than the  
319 mean we have a theoretical analytical specificity of 99.9999994%. We plan to repeat the analysis  
320 of all positive samples to further increase analytical specificity. Since our test is non-invasive  
321 with home-collection we can also offer repeat testing on a second sample to further increase  
322 specificity. These procedures will minimize the false positives due to purely technical issues.  
323 There is still the possibility of biological false positives, however, due to cross reactivity with  
324 other infectious or environmental agents. The S1 antigen appears to be specific for SARS-CoV-2  
325 (2, 3, 10) and in our series of 667 samples collected prior to 2019 we observed no false positive  
326 results.

327         Many investigations of neutralizing antibodies use antibodies directed to a different  
328 epitope, the Ribosomal Binding Domain (RBD). Therefore, we tried to assay the RNA binding  
329 domain (RBD) but found a false positive in the initial 10 unaffected controls indicating  
330 significant cross reactivity between the RBD and other viral species, disqualifying RBD for our  
331 purposes.

332         We cannot predict the eventual clinical specificity of this assay. At a minimum, the  
333 specificity is 667 / 668 or 99.985% assuming the next control sample tested would be a false  
334 positive, but the specificity is likely to be higher. Our current sensitivity is 100% for patients  
335 with symptoms severe enough to seek medical care. For all patients, including mildly  
336 asymptomatic patients, our clinical sensitivity is 88%. Since the Amperial™ assay only requires  
337 6 µL of collection fluid, several assays can be performed from the same sample. This allows all  
338 positives to be repeated to confirm the positive results, This further increasing the specificity of

339 the assay. We will offer testing of a second, independent sample for all patients testing positive.  
340 Since saliva collection is easily be performed at home, obtaining a second sample is not difficult.

341 For any laboratory test, the PPV is proportional to the prevalence of positivity in the  
342 population. A recent study demonstrated a prevalence of between 4.4% to 6% in Britain (16).  
343 Using the minimum specificity of 99.985% and a prevalence of 6% the Amperial™ saliva assay  
344 would have a minimum PPV of 96%. In contrast, a published saliva antibody detection assay  
345 reported a specificity of 98% with a similar sensitivity (89%). This specificity leads to PPV of  
346 only 69% making it an ineffective tool for population screening.

347 Our data demonstrate that the Imperial™ assay is appropriate for longitudinal screening  
348 of antibody levels, a particular utility in vaccine trials and in population monitoring following  
349 mass immunization. Since this assay is quantitative and levels appear to be stable with time,  
350 patients may be monitored from home at frequent intervals. If antibodies raised in response to  
351 vaccination do not include IgG antibodies to S1 antigen, it is easy to rapidly develop Amperial™  
352 antibody tests to any antigen. This requires adding the new antigen to the pyrrole solution and  
353 does not require significant alteration of assay conditions.

354 A particular advantage of this assay is convenience. The Orasure™ collector is simple  
355 and easy to use and does not require professional monitoring for adequate collection. Home  
356 collection relieves the burden to an already stressed health care system. Vulnerable populations  
357 such as children and the elderly can be guided through the collection process by parents or other  
358 adults. It is possible to obtain repeat samples to confirm positives and to perform longitudinal  
359 testing since the only requirement for testing is shipping th collecting kit.

360 The Amperial™ IgG test is plate-based and high-throughput. An entire plate is easily  
361 processed in 2 hours, leading to rapid turnaround time once the sample enters the laboratory.

362 There is no pre-processing of the sample required; samples are taken directly from the collection  
363 vial and placed into the assay. With standard liquid handlers, the assay may be easily automated  
364 allowing for extremely high-throughput since the Amperial™ reader is only required for the  
365 polymerization step of less than a minute at the beginning of the assay and 3 minutes for the  
366 measurement phase at the end of the assay.

367 Published data (13) and our own demonstrate a correlation between blood results and  
368 saliva results indicating that the IgG present in saliva is most likely derived from the plasma  
369 through filtration. Our data shows that saliva IgG levels are approximately 50-fold less than  
370 those in plasma necessitating a highly sensitive assay in order to detect the IgG levels in saliva.

371 There is some discussion in the literature of the role antibody testing may have in  
372 managing the COVID-19 epidemic. Alter and Seder published an editorial in the New England  
373 Journal of Medicine arguing, “Contrary to recent reports suggesting that SARS-CoV-2 RNA  
374 testing alone, in the absence of antibodies, will be sufficient to track and contain the pandemic,  
375 the cost, complexity, and transient nature of RNA testing for pathogen detection render it an  
376 incomplete metric of viral spread at the population level. Instead, the accurate assessment of  
377 antibodies during a pandemic can provide important population-based data on pathogen  
378 exposure, facilitate an understanding of the role of antibodies in protective immunity, and guide  
379 vaccine development. (14)”

380 In this article, we describe the development of a non-invasive, home collection based,  
381 exquisitely specific, and acceptably sensitive test for the presence of anti-SARS-CoV-2  
382 antibodies in saliva. This may be an important tool in controlling the pandemic and facilitating  
383 and understanding of the role of antibody production in COVID-19 immunity. Longitudinal  
384 monitoring of anti-SARS-CoV-2 IgG levels could also play a valuable role in vaccine

385 development and deployment by allowing longitudinal quantitative assessment of antibody  
386 levels. If the presence of detectable anti-COVID-19 IgG is shown to be an indicator of immunity  
387 to reinfection, measurement of these antibodies could allow individuals to safely return to work,  
388 school and community. The Amperial™ SARS-CoV-2 assay fulfills the requirements for all of  
389 these applications.

### 390 **Acknowledgements**

391 DW is supported by U54HL119893, UCLA W.M. Keck Foundation Research Award  
392 Program. SC is supported by F30DE027615.

### 393 **Disclosures**

394 CS is a founder and CEO of Liquid Diagnostics, LLC and holds equity in the company.  
395 MT is an employee and an equity holder in Liquid Diagnostics. RB is the CMO of Liquid  
396 Diagnostics and holds equity in the company. DW is an equity holder in Liquid Diagnostics, LLC.  
397 and a consultant to Mars Wrigley and Colgate-Palmolive

### 398 **References**

- 399 1. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, Liu L, Shan H, Lei C, Hui DSC, Du B, Li L,  
400 Zeng G, Yuen K-Y, Chen R, Tang C, Wang T, Chen P, Xiang J, Li S, Wang J, Liang Z,  
401 Peng Y, Wei L, Liu Y, Hu Y, Peng P, Wang J, Liu J, Chen Z, Li G, Zheng Z, Qiu S, Luo  
402 J, Ye C, Zhu S, Zhong N. 2020. Clinical Characteristics of Coronavirus Disease 2019 in  
403 China. *N Engl J Med* 382:1708–1720.
- 404 2. Interim Guidelines for COVID-19 Antibody Testing. Center for Disease Control and  
405 Prevention. 2020 Aug 1. [Cited 2020 Nov 5] [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html)  
406 [ncov/lab/resources/antibody-tests-guidelines.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html)

- 407 3. Hoffman T, Nissen K, Krambrich J, Rönnerberg B, Akaberi D, Esmaeilzadeh M, Salaneck  
408 E, Lindahl J, Lundkvist Å. 2020. Evaluation of a COVID-19 IgM and IgG rapid test; an  
409 efficient tool for assessment of past exposure to SARS-CoV-2. *Infection Ecology &*  
410 *Epidemiology* 10:1754538.
- 411 4. Montesinos I, Gruson D, Kabamba B, Dahma H, Van den Wijngaert S, Reza S, Carbone  
412 V, Vandenberg O, Gulbis B, Wolff F, Rodriguez-Villalobos H. 2020. Evaluation of two  
413 automated and three rapid lateral flow immunoassays for the detection of anti-SARS-  
414 CoV-2 antibodies. *Journal of Clinical Virology* 128:104413.
- 415 5. Döhla M, Boesecke C, Schulte B, Diegmann C, Sib E, Richter E, Eschbach-Bludau M,  
416 Aldabbagh S, Marx B, Eis-Hübinger A-M, Schmithausen RM, Streeck H. 2020. Rapid  
417 point-of-care testing for SARS-CoV-2 in a community screening setting shows low  
418 sensitivity. *Public Health* 182:170–172.
- 419 6. Zainol Rashid Z, Othman SN, Abdul Samat MN, Ali UK, Wong KK. 2020. Diagnostic  
420 performance of COVID-19 serology assays. *Malays J Pathol* 42:13–21.
- 421 7. Thevis M, Knoop A, Schaefer MS, Dufaux B, Schrader Y, Thomas A, Geyer H. 2020.  
422 Can dried blood spots (DBS) contribute to conducting comprehensive SARS-CoV-2  
423 antibody tests? *Drug Test Anal* 12:994–997.
- 424 8. Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, Peng P, Liu X, Chen Z, Huang H, Zhang  
425 F, Luo W, Niu X, Hu P, Wang L, Peng H, Huang Z, Feng L, Li F, Zhang F, Li F, Zhong  
426 N, Chen L. 2020. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-  
427 19 patients. *Emerging Microbes & Infections* 9:940–948.

- 428 9. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, Bucci E, Piacentini M, Ippolito G,  
429 Melino G. 2020. COVID-19 infection: the perspectives on immune responses. *Cell Death*  
430 *Differ* 27:1451–1454.
- 431 10. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E,  
432 Arnthorsson AO, Helgason D, Bjarnadottir K, Ingvarsson RF, Thorsteinsdottir B,  
433 Kristjansdottir S, Birgisdottir K, Kristinsdottir AM, Sigurdsson MI, Arnadottir GA,  
434 Ivarsdottir EV, Andresdottir M, Jonsson F, Agustsdottir AB, Berglund J, Eiriksdottir B,  
435 Fridriksdottir R, Gardarsdottir EE, Gottfredsson M, Gretarsdottir OS, Gudmundsdottir S,  
436 Gudmundsson KR, Gunnarsdottir TR, Gylfason A, Helgason A, Jensson BO, Jonasdottir  
437 A, Jonsson H, Kristjansson T, Kristinsson KG, Magnusdottir DN, Magnusson OT,  
438 Olafsdottir LB, Rognvaldsson S, le Roux L, Sigmundsdottir G, Sigurdsson A,  
439 Sveinbjornsson G, Sveinsdottir KE, Sveinsdottir M, Thorarensen EA, Thorbjornsson B,  
440 Thordardottir M, Saemundsdottir J, Kristjansson SH, Josefsdottir KS, Masson G,  
441 Georgsson G, Kristjansson M, Moller A, Palsson R, Gudnason T, Thorsteinsdottir U,  
442 Jonsdottir I, Sulem P, Stefansson K. 2020. Humoral Immune Response to SARS-CoV-2  
443 in Iceland. *N Engl J Med* 383:1724–1734.
- 444 11. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, Lamers  
445 MM, Sikkema RS, de Bruin E, Chandler FD, Yazdanpanah Y, Le Hingrat Q, Descamps  
446 D, Houhou-Fidouh N, Reusken CBEM, Bosch B-J, Drosten C, Koopmans MPG,  
447 Haagmans BL. 2020. Severe Acute Respiratory Syndrome Coronavirus 2–Specific  
448 Antibody Responses in Coronavirus Disease Patients. *Emerg Infect Dis* 26:1478–1488.

- 449 12. Hettegger P, Huber J, Paßecker K, Soldo R, Kegler U, Nöhammer C, Weinhäusel A.  
450 2019. High similarity of IgG antibody profiles in blood and saliva opens opportunities for  
451 saliva based serology. PLoS ONE 14:e0218456.
- 452 13. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, Li Z, Chao G, Rojas OL, Bang  
453 YM, Pu A, Christie-Holmes N, Gervais C, Ceccarelli D, Samavarchi-Tehrani P, Guvenc  
454 F, Budyłowski P, Li A, Paterson A, Yue FY, Marin LM, Caldwell L, Wrana JL, Colwill  
455 K, Sicheri F, Mubareka S, Gray-Owen SD, Drews SJ, Siqueira WL, Barrios-Rodiles M,  
456 Ostrowski M, Rini JM, Durocher Y, McGeer AJ, Gommerman JL, Gingras A-C. 2020.  
457 Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in  
458 COVID-19 patients. *Sci Immunol* 5:eabe5511.
- 459 14. Alter G, Seder R. 2020. The Power of Antibody-Based Surveillance. *N Engl J Med*  
460 383:1782–1784.
- 461 15. Ceron J, Lamy E, Martinez-Subiela S, Lopez-Jornet P, Capela-Silva F, Eckersall P,  
462 Tvarijonaviciute A. 2020. Use of Saliva for Diagnosis and Monitoring the SARS-CoV-2:  
463 A General Perspective. *JCM* 9:1491.
- 464 16. Imperial College London COVID-19 Virus Home Antibody Testing. 2020 June to  
465 September. [Cited 2020 November 5]  
466 [https://www.ipsos.com/sites/default/files/ct/news/documents/2020-](https://www.ipsos.com/sites/default/files/ct/news/documents/2020-10/covid19_anitbody_infographic_round3_241020.pdf)  
467 [10/covid19\\_anitbody\\_infographic\\_round3\\_241020.pdf](https://www.ipsos.com/sites/default/files/ct/news/documents/2020-10/covid19_anitbody_infographic_round3_241020.pdf)  
468

469 1.

470

Severity Index	Positive IgG (no. patients)	Negative IgG (no. patients)	Sensitivity (%)
0: Asymptomatic	2	0	100
1: Mild Flu-Like Symptoms	3	3	50
2: Moderate Flu-Like Symptoms	9	1	90
3: Sought Medical Attention	10	0	100
4: Admitted to Hospital	3	0	100
5: Admitted to ICU	1	0	100
6: Placed on Ventilator	2	0	100
Total	30	4	88.24


471

472

473 Table 1. Correlation of Amperial™ anti-SARS-CoV-2 IgG levels in saliva with severity of  
474 symptoms in 34 COVID positive subjects.

475

476




477

478


479 Figure 1. Schematic of the Amperial™ saliva anti-SARS-CoV-2 IgG assay. See methods for  
480 description.

481



482  
483 Figure 2. Dynamic range and linear range of Amperial™ anti-Spike S1 IgG assay. X-axis:  
484 Amount of spike in anti-SARS-CoV-2 IgG in ng / ml. Y-axis: Normalized current in nA. Panel  
485 A: 0 – 5 ng / ml Panel B: 0.1 – 0.7 ng / ml  
486






488

489 Figure 3. Competition assay of three COVID-19 patients: C1, C2, and C3. Varying amounts of

490 exogenous anti-SARS-CoV-2 IgG added to saliva of 3 different recovered COVID-19 patients.

491




492

493

494 Figure 4. Box plot of saliva matrix experiments with saliva from healthy subjects. Green dashed

495 line represents 5 standard deviations above the mean.

496



497


498 Figure 5. Healthy reference range of Amperial™ saliva anti-SARS-CoV-2 IgG assay of 667

499 unexposed subjects in (A) normalized current ( $\Delta nA$ ) with mean=24.38 and cutoff=221.47 and

500 (B) concentration (ng / ml) with mean=0.33 and cutoff=1.19.

501

502




503

504 Figure 6. Amperial™ detection of anti-Spike S1 IgG in saliva of COVID-19 (n=34) and healthy

505 subjects (n=667). Green dashed line indicates 5 SD reference range cutoff.


506



507

508 Figure 7. Clinical severity index and anti-Spike S1 IgG level in saliva.

509



510

511

512 Figure 8. COVID-19 antibody level in paired saliva and plasma of COVID-19 (n=8) subjects in a


513 blinded randomized cohort. Plasma antibodies level are measured by EUROIMMUN ELISA

514 reported in ratio (proportion of OD of calibrator to OD of sample) and saliva antibodies are

515 measured by Amperial™ in pg / ml. Green dashed line indicates 5 SD reference range cutoff of

516 Amperial™ test and red dashed line is reference range for EUROIMMUN ELISA.

517



518

519

520 Figure 9. Relationship of plasma anti-SARSCoV-2 IgG levels to saliva levels measured by

521 Amperial™ assays. (A) Panel A shows a log / log plot of plasma versus saliva levels showing a


522 clustering of the positive values with high plasma levels associated with high saliva levels on the

523 Amperial™ platform. (B) Box plot of COVID-19 (n=8) and healthy (n=5) subjects

524 demonstrating that the normalized plasma levels are approximately 50X those of saliva.

525

526



527

528 Figure 10. Longitudinal Measurement of saliva anti-SARS-CoV-2 IgG levels in 3 recovered  
529 patients. X-axis: Time after initial onset of symptoms (in weeks). Y-axis: IgG levels measured in  
530 saliva.

531